Login to Your Account

DUBLIN – European life sciences firms raised €23 million (US$26 million) in 42 crowdfunding campaigns over the last five years, according to the first ever analysis of the field, published last week by Biocom AG, a Berlin-based consultancy and research firm.
LONDON – Moves to increase patient involvement in drug development will ramp up in the next few months as the European Patients' Academy on Therapeutic Innovation (Eupati) enrolls 60 new students to its expert training course and launches an online toolbox of educational resources for patient advocates.
Analysts mulled what the approval in the European Union (EU) of Amgen Inc.'s cholesterol drug Repatha (evolocumab) might mean for the compound's fate in the U.S., and for same-class competitor Praluent (alirocumab) from Regeneron Pharmaceuticals Inc. and Sanofi SA in both regions.
More EUROPE Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: